These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 21484190)

  • 1. Proteasome inhibitors in cancer therapy.
    Crawford LJ; Walker B; Irvine AE
    J Cell Commun Signal; 2011 Jun; 5(2):101-10. PubMed ID: 21484190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibitors: a therapeutic strategy for haematological malignancy.
    Crawford LJ; Walker B; Irvine AE
    Front Biosci; 2008 May; 13():4285-96. PubMed ID: 18508511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.
    Kubiczkova L; Pour L; Sedlarikova L; Hajek R; Sevcikova S
    J Cell Mol Med; 2014 Jun; 18(6):947-61. PubMed ID: 24712303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development and pharmacology of proteasome inhibitors for the management and treatment of cancer.
    Ruggeri B; Miknyoczki S; Dorsey B; Hui AM
    Adv Pharmacol; 2009; 57():91-135. PubMed ID: 20230760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibitors in cancer therapy.
    Testa U
    Curr Drug Targets; 2009 Oct; 10(10):968-81. PubMed ID: 19548862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.
    Johnson DE
    Endocr Relat Cancer; 2015 Feb; 22(1):T1-17. PubMed ID: 24659480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
    Chen D; Frezza M; Schmitt S; Kanwar J; Dou QP
    Curr Cancer Drug Targets; 2011 Mar; 11(3):239-53. PubMed ID: 21247388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
    Narayanan S; Cai CY; Assaraf YG; Guo HQ; Cui Q; Wei L; Huang JJ; Ashby CR; Chen ZS
    Drug Resist Updat; 2020 Jan; 48():100663. PubMed ID: 31785545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?
    Selvaraju K; Mazurkiewicz M; Wang X; Gullbo J; Linder S; D'Arcy P
    Drug Resist Updat; 2015; 21-22():20-9. PubMed ID: 26183292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Proteasome inhibitor].
    Yagi H
    Nihon Rinsho; 2014 Jun; 72(6):1125-9. PubMed ID: 25016815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ubiquitin-based anticancer therapy: carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors.
    Mattern MR; Wu J; Nicholson B
    Biochim Biophys Acta; 2012 Nov; 1823(11):2014-21. PubMed ID: 22610084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ubiquitin proteasome pathway from bench to bedside.
    Orlowski RZ
    Hematology Am Soc Hematol Educ Program; 2005; ():220-5. PubMed ID: 16304384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From bortezomib to other inhibitors of the proteasome and beyond.
    Buac D; Shen M; Schmitt S; Kona FR; Deshmukh R; Zhang Z; Neslund-Dudas C; Mitra B; Dou QP
    Curr Pharm Des; 2013; 19(22):4025-38. PubMed ID: 23181572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the ubiquitin-proteasome pathway: an emerging concept in cancer therapy.
    Frezza M; Schmitt S; Dou QP
    Curr Top Med Chem; 2011 Dec; 11(23):2888-905. PubMed ID: 21824109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the ubiquitin-proteasome pathway in cancer therapy.
    Ishii Y; Waxman S; Germain D
    Anticancer Agents Med Chem; 2007 May; 7(3):359-65. PubMed ID: 17504161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the understanding of mechanisms and therapeutic use of bortezomib.
    Mujtaba T; Dou QP
    Discov Med; 2011 Dec; 12(67):471-80. PubMed ID: 22204764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line.
    Yerlikaya A; Okur E; Baykal AT; Acılan C; Boyacı I; Ulukaya E
    J Proteomics; 2015 Jan; 113():315-25. PubMed ID: 25305590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the proteasome pathway.
    Tsukamoto S; Yokosawa H
    Expert Opin Ther Targets; 2009 May; 13(5):605-21. PubMed ID: 19397479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.
    Shahshahan MA; Beckley MN; Jazirehi AR
    Am J Cancer Res; 2011; 1(7):913-24. PubMed ID: 22016836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma.
    Jayaweera SPE; Wanigasinghe Kanakanamge SP; Rajalingam D; Silva GN
    Front Oncol; 2021; 11():740796. PubMed ID: 34858819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.